Arbutus Biopharma Corp (LTS:0SGC)
$ 3.8501 -0.0293 (-0.76%) Market Cap: 747.58 Mil Enterprise Value: 607.19 Mil PE Ratio: 0 PB Ratio: 5.95 GF Score: 43/100

Arbutus Biopharma Corp AB-729 Clinical Update Conference Call Transcript

May 18, 2020 / 08:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the AB-729 Clinical Update. (Operator Instructions) Please be advised that today's conference call is being recorded. (Operator Instructions)

I would -- at this time, I would like to hand the conference over to Ms. Pam Murphy. Thank you. Ma'am, please go ahead.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Good afternoon. And hopefully, everyone has been able to connect to the AB-729 clinical update webcast, and that you are able to access the slides. With me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Dr. Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. Bill will begin with a quick summary of the data and planned next steps for AB-729. Gaston will then walk you through the additional positive clinical data for AB-729 described in today's press release. After Gaston's presentation, we'll then open up the call for Q&A.

Before we begin,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot